Drug intelligence / Profile preview

AISA-023

Development stage: Preclinical
Lead developer: Aisa Pharma
Modality: Small Molecules

Overview

AISA-023 is a small molecule drug initially developed by Aisa Pharma, Inc. for the treatment of nervous system diseases and other conditions. Its primary active indications include migraine disorders and renal colic. The drug is currently in the discovery phase of development, with no clinical trials or approvals reported as of March 2025[1][2][3]. The specific mechanism of action has not been publicly disclosed.

Other names: AISA-023AISA023AISA 023

Beyond the preview

Go deeper on AISA-023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AISA-023.

Explore the full profile